NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
The brokerage firm Motilal Oswal Financial Services has reiterated its Buy rating on Privi Speciality Chemicals Ltd. with a target price of Rs 3900, based on 27x FY28E EPS i.e. three year average – one year forward price/earning, implying a potential upside of 24% from the current market price.
-
Indian Markets Turning Corner After Two Tough Years, Says Sandeep Tandon -
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI
According to the brokerage Privi Speciality Chemicals is well-positioned for sustainable growth, supported by its relatively low crude-linked exposure (~25%), which provides resilience against ongoing energy market volatility and supports margin stability.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
The upcoming mergers with Privi Fine Science, Privi BiotechnologiesL and PRIGIV, joint venture with Givauda are expected to expand its specialty aroma portfolio. Consequently, this is expected to drive revenue growth and enhance earnings.
Further, the company's expansion into high-value specialty molecules such as Maltol, Ethyl Maltol, and Cyclopentanone (from the Corn Cob route), coupled with backward integration into Furfural, is expected to contribute meaningfully to revenues while improving cost competitiveness and margins.
The brokerage expects Privi to clock a compound annual growth rate of 25%/27%/34% in revenue/Ebitda/PAT during FY26-28.
Motilal Oswal has reiterated its Buy rating on the stock.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
